問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Shin Kong Memorial Wu Ho-Su Hospital (在職)

Division of Neurology

更新時間：2023-09-19

葉旭霖
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

2Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

葉旭霖

Shin Kong Memorial Wu Ho-Su Hospital

Division of Neurology

List

5Cases

2022-06-01 - 2027-10-31

Phase II

Active
Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • Condition/Disease

    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • Test Drug

    Efgartigimod (ARGX-113)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting1Sites

Terminated5Sites

2023-01-16 - 2025-08-30

Phase III

Active
A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA

  • Condition/Disease

    Prevention of Ischemic Stroke

  • Test Drug

    asundexianPlacebo

Participate Sites
23Sites

Not yet recruiting6Sites

Recruiting17Sites

2012-05-01 - 2018-12-03

IIT

Phase III

Completed
Extending the time for Thrombolysis in Emergency Neurological Deficits

  • Condition/Disease

    Acute Ischaemic Stroke

  • Test Drug

    Tissue Plasminogen Activator (tPA)

Participate Sites
9Sites

Suspended8Sites

Study ended1Sites

蔡崇豪
China Medical University Hospital

Division of Neurology

2014-02-01 - 2016-01-31

Phase III

Acute Stroke Or Transient IsChemic Attack TReated with Aspirin or Ticagrelor and Patient OutcomES

  • Condition/Disease

    Patients with an acute cerebral ischemic event (minor stroke/high-risk TIA) and high risk of subsequent ischemic stroke, who could be randomised within 24 hours of symptom onset

  • Test Drug

    Ticagrelor

Participate Sites
11Sites

Terminated10Sites

Study ended1Sites

林瑞泰
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2018-01-22 - 2019-12-31

Phase III

A Randomized, Double-Blinded, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack

  • Condition/Disease

    Acute Ischemic Stroke or Transient ischaemic attack

  • Test Drug

    BRILINTA

Participate Sites
16Sites

Recruiting15Sites

Study ended1Sites

李宗海
Linkou Chang Gung Medical Foundation

Division of Neurology

林秀芬
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB